Friedrich Asmus, MD

Biography

Friedrich “Fritz” Asmus has over 20 years of experience in translational and clinical research, spanning academia, med-/biotech companies, and big pharma. He has headed ophthalmic clinical development programs in the US, Europe, and Asia for over a decade. He led the clinical trials for Oxular`s Oxulumis®, a microcatherization device for suprachoroidal treatments, and guided early phase intravitreal anti-sense oligonucleotide therapies for rare and ultra-rare retinal diseases at ProQR. Friedrich contributed to Bayer’s Eylea® program, developing the clinical strategy for Eylea® HD. He is a board-certified neurologist, lecturer at the University Hospital of Tuebingen, and a licensed pharmacist, with over 50 published scientific papers.